Homocysteine: A biomarker in neurodegenerative diseases

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 3, 2011, Pages 435-441

  Herrmann, Wolfgang ^a   Obeid, Rima ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; cognitive impairment; dementia; folate; homocysteine; stroke; vitamin B12; vitamin deficiency

Indexed keywords

BIOLOGICAL MARKER; HOMOCYSTEINE; VITAMIN B GROUP;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; BRAIN ATROPHY; COGNITIVE DEFECT; DEGENERATIVE DISEASE; EPIDEMIOLOGICAL DATA; HUMAN; HYPERHOMOCYSTEINEMIA; MULTIINFARCT DEMENTIA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REVIEW; STROKE; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

BIOLOGICAL MARKERS; HOMOCYSTEINE; HUMANS; NEURODEGENERATIVE DISEASES; VITAMIN B 12 DEFICIENCY;

EID: 79952783461     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.084     Document Type: Review

References (74)

1. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006;580:2994-3005. (Pubitemid 43744523)
2. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403. (Pubitemid 44108123)
3. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of oxidative wcorrectedx stress in Alzheimer's disease. Am J Pathol 1992;140:621-8.
4. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 1997;68: 2061-9. (Pubitemid 27176143)
5. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's betapeptide from biological fluids. Nature 1992;359:325-7.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-6. (Pubitemid 34790756)
7. Wimo A, Winblad B, guero-Torres H, von SE. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17:63-7. (Pubitemid 36736838)
8. Johnson JK, Pa J, Boxer AL, Kramer JH, Freeman K, Yaffe K. Baseline predictors of clinical progression among patients with dysexecutive mild cognitive impairment. Dement Geriatr Cogn Disord 2010;30:344-51.
9. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004;62:1148-55. (Pubitemid 38456510)
10. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: Efficacy of long-term treatment of hypertension. Stroke 2006;37:1165-70. (Pubitemid 43731856)
11. Hin H, Clarke R, Sherliker P, Atoyebi W, Emmens K, Birks J, et al. Clinical relevance of low serum vitamin B12 concentrations in older people: The Banbury B12 study. Age Ageing 2006;35:416-22. (Pubitemid 43941812)
12. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007;85:193-200. (Pubitemid 46067634)
13. Scott TM, Peter I, Tucker KL, Arsenault L, Bergethon P, Bhadelia R, et al. The Nutrition, Aging, and Memory in Elders (NAME) study: Design and methods for a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psychiatry 2006;21:519-28. (Pubitemid 44043752)
14. Khatri M, Wright CB, Nickolas TL, Yoshita M, Paik MC, Kranwinkel G, et al. Chronic kidney disease is associated with white matter hyperintensity volume: The Northern Manhattan Study (NOMAS). Stroke 2007;38:3121-6. (Pubitemid 350175724)
15. Weiner DE, Bartolomei K, Scott T, Price LL, Griffith JL, Rosenberg I, et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am J Kidney Dis 2009;53:438-47.
16. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346: 476-83. (Pubitemid 34441738)
17. Folstein M, Folstein S. Functional expressions of the aging brain. Nutr Rev 2010;68(Suppl 2):S70-3.
18. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, et al. Association of plasma total homocysteine levels with subclinical brain injury: Cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008;65:642-9. (Pubitemid 351679660)
19. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS ONE 2010;5: E12244.
20. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine is elevated in elderly patients with memory complaints and vascular disease. Dement Geriatr Cogn Disord 2007;23:321-6. (Pubitemid 46631939)
21. Obeid R, Schorr H, Eckert R, Herrmann W. Vitamin B12 status in the elderly as judged by available biochemical markers. Clin Chem 2004;50:238-41. (Pubitemid 38125734)
22. Pinto X, Vilaseca MA, Garcia-Giralt N, Ferrer I, Pala M, Meco JF, et al. Homocysteine and the MTHFR 677C->T allele in premature coronary artery disease. Case control and family studies. Eur J Clin Invest 2001;31:24-30. (Pubitemid 32151118)
23. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181-9. (Pubitemid 32880357)
24. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull 2008;29:S20-34.
25. de JJ, Kooy A, Lehert P, Wulffele MG, van der KJ, Bets D, et al. Long-term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. Br Med J 2010;340:c2181.
26. Prins ND, den HT, Hofman A, Koudstaal PJ, Jolles J, Clarke R, et al. Homocysteine and cognitive function in the elderly: The Rotterdam Scan Study. Neurology 2002;59:1375-80. (Pubitemid 35285990)
27. McCracken C, Hudson P, Ellis R, McCaddon A. Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study. Am J Clin Nutr 2006; 84:1406-11. (Pubitemid 44912825)
28. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, Sacco RL. Total homocysteine and cognition in a tri-ethnic cohort: The Northern Manhattan Study. Neurology 2004;63:254-60. (Pubitemid 38971123)
29. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004;80:114-22. (Pubitemid 41115564)
30. Herrmann W, Herrmann M, Obeid R. Hyperhomocysteinaemia: A critical review of old and new aspects. Curr Drug Metab 2007;8:17-31. (Pubitemid 46043889)
31. Popp J, Lewczuk P, Linnebank M, Cvetanovska G, Smulders Y, Kolsch H, et al. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis 2009; 18:819-28.
32. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002;70:694-702. (Pubitemid 35397143)
33. Rao AM, Baskaya MK, Maley ME, Kindy MS, Dempsey RJ. Beneficial effects of S-adenosyl-L-methionine on blood-brain barrier breakdown and neuronal survival after transient cerebral ischemia in gerbils. Brain Res Mol Brain Res 1997;44:134-8. (Pubitemid 27050869)
34. Trovarelli G, De Medio GE, Porcellati S, Stramentinoli G, Porcellati G. The effect of S-adenosyl-L-methionine on ischemiainduced disturbances of brain phospholipid in the gerbil. Neurochem Res 1983;8:1597-609. (Pubitemid 14157631)
35. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096-8.
36. Serot JM, Christmann D, Dubost T, Bene MC, Faure GC. CSFfolate levels are decreased in late-onset AD patients. J Neural Transm 2001;108:93-9. (Pubitemid 32692616)
37. Nurk E, Refsum H, Tell GS, Engedal K, Vollset SE, Ueland PM, et al. Plasma total homocysteine and memory in the elderly: The Hordaland Homocysteine study. Ann Neurol 2005; 58:847-57. (Pubitemid 41746874)
38. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-13. (Pubitemid 34441260)
39. Budge M, Johnston C, Hogervorst E, de JC, Milwain E, Iversen SD, et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci 2000;903: 407-10. (Pubitemid 30251582)
40. Sachdev PS. Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1152-61. (Pubitemid 41383514)
41. Schafer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS. Homocysteine and cognitive function in a population- based study of older adults. J Am Geriatr Soc 2005;53: 381-8. (Pubitemid 41623514)
42. Kado DM, Karlamangla AS, Huang MH, Troen A, Rowe JW, Selhub J, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 2005;118:161-7. (Pubitemid 40202865)
43. Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 2003;53:214-21. (Pubitemid 36164003)
44. Kivipelto M, Annerbo S, Hultdin J, Backman L, Viitanen M, Fratiglioni L, et al. Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimers disease: A prospective study. Eur J Neurol 2009;16:808-13.
45. Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: A longitudinal study. Neurology 2010;75:1408-14.
46. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-9. (Pubitemid 28194997)
47. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-55. (Pubitemid 28525506)
48. Smith AD. The worldwide challenge of the dementias: A role for B vitamins and homocysteine? Food Nutr Bull 2008;29: S143-72.
49. McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001;12:309-13. (Pubitemid 32656662)
50. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005;82:636-43.
51. Obeid R, McCaddon A, Herrmann W. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and neuropsychiatric diseases. Clin Chem Lab Med 2007;45:1590-606. (Pubitemid 350232981)
52. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002;59:787-93. (Pubitemid 34517761)
53. Matsui T, Arai H, Yuzuriha T, Yao H, Miura M, Hashimoto S, et al. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 2001;32:1116-9. (Pubitemid 32825794)
54. Polyak Z, Stern F, Berner YN, Sela BA, Gomori JM, Isayev M, et al. Hyperhomocysteinemia and vitamin score: Correlations with silent brain ischemic lesions and brain atrophy. Dement Geriatr Cogn Disord 2003;16:39-45. (Pubitemid 36469812)
55. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002;51:285-9. (Pubitemid 34206283)
56. Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet 1999;353:1586-7. (Pubitemid 29219212)
57. Vermeulen EG, Stehouwer CD, Valk J, van der KM, van den BM, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: A placebo-controlled, randomized trial. Eur J Clin Invest 2004;34:256-61. (Pubitemid 38553594)
58. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam Study. Arch Intern Med 1999;159:38-44. (Pubitemid 29044117)
59. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924-30. (Pubitemid 24291274)
60. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteine- lowering therapy and stroke risk, severity, and disability. Additional findings from the HOPE 2 trial. Stroke 2009; 40:1365-72.
61. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med 2010;170:1622-31.
62. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: A metaanalysis. Lancet 2007;369:1876-82. (Pubitemid 46829358)
63. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine- lowering therapy with folic acid in stroke prevention: A meta-analysis. Stroke 2010;41:1205-12.
64. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-43. (Pubitemid 43739455)
65. Yang Q, Friedmann JM, Botto LD. Improvement in stroke and ischemic heart disease mortality in the United States 1990- 2001. Clin Chem Lab Med 2005;43:A14.
66. Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, et al. Plasma Abeta, homocysteine, and cognition: The Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 2009;72:268-72.
67. Flicker L, Martins RN, Thomas J, Acres J, Taddei K, Vasikaran SD, et al. B-vitamins reduce plasma levels of beta amyloid. Neurobiol Aging 2008;29:303-5.
68. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L. Homocysteine and depression in later life. Arch Gen Psychiatry 2008;65:1286-94.
69. Almeida OP, Marsh K, Alfonso H, Flicker L, Davis TM, Hankey GJ. B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol 2010;68: 503-10.
70. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003;26:137-46. (Pubitemid 36183675)
71. Nicolia V, Fuso A, Cavallaro RA, Di LA, Scarpa S. B vitamin deficiency promotes tau phosphorylation through regulation of GSK3beta and PP2A. J Alzheimers Dis 2010;19:895-907.
72. Hrncic D, Rasic-Markovic A, Krstic D, Macut D, Djuric D, Stanojlovic O. The role of nitric oxide in homocysteine thiolactone- induced seizures in adult rats. Cell Mol Neurobiol 2010;30:219-31.
73. Matte C, Mackedanz V, Stefanello FM, Scherer EB, Andreazza AC, Zanotto C, et al. Chronic hyperhomocysteinemia alters antioxidant defenses and increases DNA damage in brain and blood of rats: Protective effect of folic acid. Neurochem Int 2009;54:7-13.
74. Stanojlovic O, Rasic-Markovic A, Hrncic D, Susic V, Macut D, Radosavljevic T, et al. Two types of seizures in homocysteine thiolactone-treated adult rats, behavioral and electroencephalographic study. Cell Mol Neurobiol 2009;29:329-39.